| Name | Title | Contact Details |
|---|
FOREO is a Swedish multi-national beauty brand established and headquartered Stockholm, Sweden.
Capnia, Inc., a privately held company headquartered in Redwood City, California, develops diagnostics based on its proprietary Sensalyze™ technology for precision metering of gas flow.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Diagnostic Imaging, P.C is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A new standard for virtual heart care. Heartbeat is a complete telehealth platform for cardiology that incorporates telemedicine, remote diagnostics, and digital heart health programs. Learn more